Immunome (IMNM) Income from Continuing Operations (2019 - 2026)
Immunome's (IMNM) quarterly Income from Continuing Operations came in at 244246000.0 in Q1 2026, down 443.98% YoY from 71006341.37 in Q1 2025, and down 235.2% on a QoQ basis from 72866000.0 in Q4 2025.
Immunome (IMNM) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Income from Continuing Operations data on file, last reported at 244246000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 443.98% year-over-year to 244246000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 489318000.0 (down 48.04% YoY) and the FY2025 annual result came in at 404781000.0, up 1.88% from the prior year.
- Income from Continuing Operations slipped to 244246000.0 in Q1 2026, from 72866000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 4571000.0 in Q1 2023 to a low of 244246000.0 in Q1 2026.
- A 5-year average of 66231176.47 and a median of 70303000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 2796.5% — and 2025, when it surged 66.09%.
- Tracing IMNM's Income from Continuing Operations over 5 years: stood at 8079000.0 in 2022, then slumped by 1072.36% to 94715000.0 in 2023, then increased by 12.08% to 83270000.0 in 2024, then rose by 12.49% to 72866000.0 in 2025, then tumbled by 235.2% to 244246000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 244246000.0 (Q1 2026), 72866000.0 (Q4 2025), and 101903000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | -248.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -248.28 Mn |
| Mar 31, 2026 | -244.25 Mn |
| Dec 31, 2025 | -72.87 Mn |
| Sep 30, 2025 | -101.90 Mn |
| Jun 30, 2025 | -70.30 Mn |
| Mar 31, 2025 | -44.90 Mn |
| Dec 31, 2024 | -83.27 Mn |
| Sep 30, 2024 | -116.13 Mn |
| Jun 30, 2024 | -86.23 Mn |
| Mar 31, 2024 | -132.40 Mn |
| Dec 31, 2023 | -94.72 Mn |
| Sep 30, 2023 | -15.83 Mn |
| Jun 30, 2023 | -16.07 Mn |
| Mar 31, 2023 | -4.57 Mn |
| Dec 31, 2022 | -8.08 Mn |
| Sep 30, 2022 | -11.93 Mn |
| Jun 30, 2022 | -10.73 Mn |
| Mar 31, 2022 | -11.75 Mn |
| Dec 31, 2021 | -7.76 Mn |
| Sep 30, 2021 | -7.72 Mn |